

## hTERT US PATENT GRANTED

- US Patent No 11,391,738 granted covering the hTERT technology
- Provides further IP protection for hTERT in the USA for cancer applications beyond bladder cancer

**Melbourne, Australia, 22 July 2022:** INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) announces that United States of America Patent No 11,391,738 entitled ‘Method of detecting cancer’ was issued by the United States Patent and Trademark Office to Sienna Cancer Diagnostic Ltd, a subsidiary of INOVIQ.

US patent 11,391,738 is due to expire on 11 March 2035 and claims use of the Company’s telomerase antibody to resolve inconclusive cytology and detect malignant cells.

CEO Dr Leearne Hinch said: *“This application is a continuation of US patent 10,338,072 and provides additional coverage of our hTERT assay for telomerase-based detection of cancers other than bladder cancer, such as thyroid and breast cancer.”*

The hTERT test is an immunocytochemistry (ICC) assay that detects hTERT, a component of telomerase, which is upregulated in most human epithelial cancers. The present test is used as an adjunct to urine cytology, assisting in the diagnosis of bladder cancer.

*Authorised by the Company Secretary, Tony Di Pietro.*

– ENDS –

### COMPANY CONTACTS

**Dr Leearne Hinch**  
Chief Executive Officer  
E: [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M: +61 400 414 416

**Dr Geoff Cumming**  
Non-Executive Chairman  
E: [geoff.cumming@inoviq.com](mailto:geoff.cumming@inoviq.com)  
M: +61 417 203 021

**Jane Lowe**  
IR Department  
E: [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)  
M: +61 411 117 774

### ABOUT INOVIQ

INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising innovative diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see [www.inoviq.com](http://www.inoviq.com).

### FORWARDING LOOKING STATEMENTS

This announcement contains certain ‘forward-looking statements’ within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as ‘may’, ‘should’, ‘expect’, ‘anticipate’, ‘estimate’, ‘scheduled’ or ‘continue’ or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and

these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.